Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients.
about
Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise reviewNew approaches in the treatment of hepatitis CProfile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infectionNK cell function and receptor diversity in the context of HCV infectionImpact of new treatment options for hepatitis C virus infection in liver transplantationHepatitis C in Special Patient Cohorts: New Opportunities in Decompensated Liver Cirrhosis, End-Stage Renal Disease and Transplant MedicineDrug-Drug Interactions with the NS3/4A Protease Inhibitor SimeprevirEfficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus InfectionDual antiviral therapy for HIV and hepatitis C - drug interactions and side effects.Advances in hepatitis C therapies.What does the pharmacological future of treating chronic hepatitis C look like?A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease.Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy.New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs).Drug interactions in HIV-infected patients treated for hepatitis C.Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.Iatrogenic Cushing Syndrome from Interaction Between Ritonavir and Oral Budesonide During Direct Acting Antiviral Hepatitis C TherapyParitaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C.An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin.Removal from liver transplantation list of an hepatitis C virus-HIV co-infected patient after successful treatment with sofosbuvir and daclatasvir.Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction.Effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience.Development of a Robust UPLC Method for Simultaneous Determination of a Novel Combination of Sofosbuvir and Daclatasvir in Human Plasma:
P2860
Q26747705-065C4846-EE55-4EF7-AFC7-94B76AC3CDABQ26773271-FCBECFE3-C9D6-4B85-AB22-A68258A882F5Q26775825-36687AB1-21EC-4081-8AFF-57EF84496684Q26781537-055A19C7-02F0-4885-BD86-6128ACFF65BCQ26782017-359A6627-D698-4C60-99B9-D006FB36C7B0Q26801198-FC717A87-EE20-45C9-9C39-91B49A43E074Q28084266-91916670-D8B9-4835-A798-A54041808E3BQ36077546-2222C93B-9D0E-43C7-B118-308855342E7CQ38554604-656FB7BF-B05E-4B57-8976-D288E56D3512Q38556401-0394ED71-F91B-4DC7-A4E9-0C0345E76EB4Q38569681-7B776D06-9BCF-4D88-8B07-A910879594BBQ38611155-9D497678-ED24-4E4D-828E-92B4A5D40920Q38657207-F41A8E0D-2075-4DA3-A698-29223EFF6E76Q39016874-A7B677E4-DCD7-416B-A0E3-96DF161348D3Q40143109-480D9DE1-4AD3-4DCA-9618-FF25ECC297B1Q40355278-3DB1D185-25C9-4F1D-A575-18B5E1B244A1Q40473486-5927374E-A68E-4AB1-BC5F-1434133F822CQ40539589-21789FFC-22A6-4BB3-B42F-EBD718FBA5E1Q40878993-587CE465-F7C1-46BE-B719-AB0D0773C126Q41434717-1555BABC-164C-4B16-985B-C72636E61538Q42148776-46AD33A8-E46F-4F02-A8F0-EAC395CF5F98Q43881640-9740AE18-AC98-4D90-99D7-D4120F3AB25CQ51754955-05816C09-C894-4F39-A007-D28E3E1A1D19Q55407931-586E5D08-87BB-4C08-A628-DC1A3E505B1DQ58699240-31224389-C7AB-44C1-8F0A-3B5657A51783
P2860
Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Drug Interactions With Direct- ...... r HIV and Transplant Patients.
@en
type
label
Drug Interactions With Direct- ...... r HIV and Transplant Patients.
@en
prefLabel
Drug Interactions With Direct- ...... r HIV and Transplant Patients.
@en
P2093
P2860
P356
P1476
Drug Interactions With Direct- ...... r HIV and Transplant Patients.
@en
P2093
Eric M Yoshida
Nilufar Partovi
Sarah Burgess
Siegfried R Erb
Vladimir Marquez Azalgara
P2860
P304
P356
10.1177/1060028015576180
P407
P577
2015-03-13T00:00:00Z